Fabbri Margherita, Leodori Giorgio, Fernandes Ricardo M, Bhidayasiri Roongroj, Marti Maria Jose, Colosimo Carlo, Ferreira Joaquim J
Neurotox Res. 2016 Jan;29(1):105-17. doi: 10.1007/s12640-015-9565-5.
The formation of neutralizing antibodies (NAbs) directed specifically against the active neurotoxin part of the botulinum neurotoxin (BoNT) complex is often cited as a major cause of secondary non-responsiveness (SnR) to treatment. This systematic and meta-analytic review evaluates the frequency of NAbs among patients treated with BoNT therapy for any clinical indication. A comprehensive database search strategy was designed to retrieve relevant clinical data from the published literature up to April 2013. All English-language publications that analyzed NAbs prevalence in more than ten patients were included, regardless of BoNT formulation, assay method, and study design. For the meta-analysis, patients were divided into three categories: secondary nonresponse (SnR) patients, clinically responding patients and all patients, independently of BoNT responsiveness. The meta-analysis included 61 studies reporting data for 8525 patients; 4972 dystonic patients, 1170 patients with spasticity, 294 patients with urologic indications, 396 patient with hyperhidrosis, 1659 patients with glabellar line, and 34 patients with hypersalivation. Among the ‘‘all patients’’ group NAbs frequency was 20%for dystonia, 5.9%for spasticity, and 2.7% for urologic patients and 1.1% for other conditions. The prevalence of NAbs was lower (3.5%) among clinically responding patients and higher in 53.5%SnR patients. About a half of patients with SnR do not have NAbs. NAbs was high among patients treated with RIMA but it was not associated with clinical non-responsiveness. Meta-analysis of the frequency of NAbs and SnR are limited by the heterogeneity of study design and reported outcomes. Indeed the analysis of several factors that can influence the development of NAbs, i.e.,MHCof patients, frequency and site of injection, injection technique, cumulative dose, and toxin denaturation, was not specifically evaluated due to the paucity and heterogeneity of data. The identification of all these missing data should be taken into account in order to improve the methodology of future studies.
特异性针对肉毒杆菌神经毒素(BoNT)复合物活性神经毒素部分的中和抗体(NAbs)的形成,常被认为是治疗继发性无反应(SnR)的主要原因。本系统评价和荟萃分析评估了接受BoNT治疗的患者中NAbs的出现频率,这些患者具有任何临床指征。设计了全面的数据库检索策略,以检索截至2013年4月已发表文献中的相关临床数据。纳入了所有分析十名以上患者中NAbs患病率的英文出版物,无论BoNT制剂、检测方法和研究设计如何。对于荟萃分析,患者被分为三类:继发性无反应(SnR)患者、临床有反应患者和所有患者,与BoNT反应性无关。荟萃分析纳入了61项研究,报告了8525例患者的数据;4972例肌张力障碍患者、1170例痉挛患者、294例有泌尿系统指征的患者、396例多汗症患者、1659例眉间纹患者和34例流涎过多患者。在“所有患者”组中,肌张力障碍患者的NAbs频率为20%,痉挛患者为5.9%,泌尿系统疾病患者为2.7%,其他情况患者为1.1%。临床有反应患者中NAbs的患病率较低(3.5%),而在53.5%的SnR患者中较高。约一半的SnR患者没有NAbs。接受RIMA治疗的患者中NAbs水平较高,但与临床无反应无关。NAbs频率和SnR的荟萃分析受到研究设计和报告结果异质性的限制。实际上,由于数据的匮乏和异质性,未对几个可能影响NAbs产生的因素进行具体评估,即患者的MHC、注射频率和部位、注射技术、累积剂量和毒素变性。为了改进未来研究的方法,应考虑识别所有这些缺失数据。